Try a new search

Format these results:

Searched for:

in-biosketch:true

person:kruppl01

Total Results:

616


Safety and tolerability of Copaxone (R) in paediatric patients with relapsing-remitting multiple sclerosis [Meeting Abstract]

Krupp, L; Banwell, BL; Picone, M; Dunn, J; Weinstock-Guttman, B; Pardo, L
ISI:000232249900307
ISSN: 1352-4585
CID: 2235432

Viral exposures in pediatric multiple sclerosis: Data from a multinational collaborative study [Meeting Abstract]

Banwell, B; Tellier, R; Krupp, L; Bar-Or, A; Kennedy, J; Tenembaum, S; Boiko, A; Bykova, O; Belman, A; Mah, J; Stoian, C; Ness, J; Rensel, M; Hahn, J; Weinstock-Guttman, B; Yeh, A; Waubant, E; Farrell, K; Freedman, M; Bhan, V; Dilenge, M; Iivanainen, M; Kremenchutzky, M; Ruggieri, M
ISI:000227841502111
ISSN: 0028-3878
CID: 2236722

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

Krupp, L B; Christodoulou, C; Melville, P; Scherl, W F; MacAllister, W S; Elkins, L E
OBJECTIVE: To determine the effect of donepezil in treating memory and cognitive dysfunction in multiple sclerosis (MS). METHODS: This single-center double-blind placebo-controlled clinical trial evaluated 69 MS patients with cognitive impairment who were randomly assigned to receive a 24-week treatment course of either donepezil (10 mg daily) or placebo. Patients underwent neuropsychological assessment at baseline and after 24 weeks of treatment. The primary outcome was change in verbal learning and memory on the Selective Reminding Test (SRT). Secondary outcomes included other tests of cognitive function, patient-reported change in memory, and clinician-reported impression of cognitive change. RESULTS: Donepezil-treated patients showed significant improvement in memory performance on the SRT compared to placebo (p = 0.043). The benefit of donepezil remained significant after controlling for various covariates including age, Expanded Disability Status Scale, baseline SRT score, reading ability, MS subtype, and sex. Donepezil-treated patients did not show significant improvements on other cognitive tests, but were more than twice as likely to report memory improvement than those in the placebo group (p = 0.006). The clinician also reported cognitive improvement in almost twice as many donepezil vs placebo patients (p = 0.036). No serious adverse events related to study medication occurred, although more donepezil (34.3%) than placebo (8.8%) subjects reported unusual/abnormal dreams (p = 0.010). CONCLUSIONS: Donepezil improved memory in MS patients with initial cognitive impairment in a single center clinical trial. A larger multicenter investigation of donepezil in MS is warranted in order to more definitively assess the efficacy of this intervention
PMID: 15534239
ISSN: 1526-632x
CID: 69684

Normative data for the selective reminding test: a random digit dialing sample

Scherl, William F; Krupp, Lauren B; Christodoulou, Christopher; Morgan, Tina M; Hyman, Leslie; Chandler, Barbara; Coyle, Patricia K; MacAllister, William S
Healthy control participants (46 women, M age=44.3 yr., SD=7.6; 29 men) were recruited to undergo a comprehensive neuropsychological battery and serve as a comparison group in a study of cognitive functioning in patients with Lyme isease. Participants were selected using Mitofsky-Waksberg random digit dialing. The Buschke 12-word, six-trial Selective Reminding Test was administered as part of the neuropsychological battery and normative data are presented stratified by age and sex. Performance on alternate forms of this measure were examined. Mean education, intelligence quotient, and Wide Range Achievement Test-3 Reading scores are reported
PMID: 15587227
ISSN: 0033-2941
CID: 69683

Unexpected demographic profile in pediatric MS [Meeting Abstract]

Krupp, LB; MacAllister, WS; Milazzo, M; Belman, AL; Christodoulou, C; Melville, P; Scherl, W; Pediatric MS Study Grp
ISI:000223761100216
ISSN: 0364-5134
CID: 2154042

Treatment of childhood and adolescent MS with interferon-beta-1b [Meeting Abstract]

Krupp, L; Banwell, B; Boiko, A; Eraksoy, M; Freedman, M; Pohl, D; Reder, AT
ISI:000225459800544
ISSN: 1352-4585
CID: 2233992

Viral exposures in paediatric multiple sclerosis: preliminary data from a multinational collaborative study [Meeting Abstract]

Banwell, B; Tellier, R; Krupp, L; Bar-Or, A; Kennedy, J; Tenembaum, S; Belman, A; Ness, J; Hahn, J; Waubant, E; Mah, J; Stoian, C; Rensel, M; Farrell, K; Freedman, M; Bhan, V; Dilenge, M; Ruggieri, M; Iivanainen, M; Weinstock-Guttmann, B; Boiko, A
ISI:000225459800232
ISSN: 1352-4585
CID: 2234362

Effects of donepezil on memory and cognition in multiple sclerosis: Comprehensive analysis of the AIMS study [Meeting Abstract]

Krupp, LB; Christodoulou, C; Melville, P; Scherl, WF; MacAllister, WS; Elkins, LE; AIMS Study Grp
ISI:000220761900449
ISSN: 0028-3878
CID: 2234472

Fatigue in multiple sclerosis : a guide to diagnosis and management

Krupp, Lauren B
New York : Demos, 2004
Extent: xiii, 93 p. ; 23 cm
ISBN: 9781888799811
CID: 2234542

Clinical features and disease-modifying therapy experience in paediatric multiple sclerosis [Meeting Abstract]

Krupp, L; Pardo, L; Vitt, D
ISI:000225459800292
ISSN: 1352-4585
CID: 2235462